

REMARKS

This Amendment is made in response to the Official Action mailed March 31, 2011. A Terminal Disclaimer accompanies this Amendment. In addition, a Supplemental Information Disclosure Statement is enclosed. Claims 9, 10, 12, 14-18 and 20-41 have been cancelled without prejudice. To the extent that the cancelled claims relate to non-elected subject matter, Applicants reserve the right to file one or more continuation or divisional applications directed to that subject matter. Accordingly, claims 1-8, 11, 13 and 19 are now pending in this application and are directed to elected subject matter. Applicants urge that the amendments place the claims into condition for allowance. Reconsideration and withdrawal of the objections to and rejections of this application are respectfully requested in view of the above amendments, and further, in view of the following remarks.

Claims 1-8, 11, 13 and 19 have been provisionally rejected on the ground of non-statutory obviousness-type double patenting, as being unpatentable in view of the claims of co-pending U.S. Application Nos. 11/575,416 (Attorney Docket No. PU61051) and 11/931,189 (Attorney Docket No. PU61432), in view of Patani et al. Although Applicants do not agree with the rejection, in order to facilitate allowance of this application, a Terminal Disclaimer is enclosed in compliance with 37 CFR 1.321 and 37 CFR 3.73(b).

In view of the above remarks, reconsideration of this application and allowance of the claims are earnestly solicited. Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned agent at the number below.

Respectfully Submitted,

/Nora L. Stein/
Nora L. Stein
Attorney for Applicants
Registration No.36,689

GlaxoSmithKline Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5044
Facsimile (610) 270-5090